Today’s Daily Dose brings you news about AbbVie’s SELECT-BEYOND trial results; Aldeyra’s clinical trial catalyst to watch out for today; Fennec’s uplisting; Peregrine’s quarterly results; Pulse Bio’s withdrawal of 510(k) for PulseTx System and appointment of a new CEO at TEVA.
AbbVie’s (ABBV) phase III clinical trial of investigational Upadacitinib (ABT-494) in patients with moderate to severe rheumatoid arthritis, who did not adequately respond or were intolerant to treatment with biologic DMARDs, has yielded positive results.
Results of the trial, dubbed SELECT-BEYOND, showed that after 12 weeks of treatment, both once-daily doses of Upadacitinib (15 mg and 30 mg) met the study’s primary endpoints of ACR20 and low disease activity. All ranked secondary endpoints were also achieved with both doses.
ACR20 is defined as American College of Rheumatology 20 percent improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.
ABBV touched a new all-time high of $87.10 on Monday, before closing the day’s trading at $87.00, up 1.95%.
Aldeyra Therapeutics Inc. (ALDX) is scheduled to announce results from its phase IIa clinical trial of ADX-102 in Dry Eye Disease on Tuesday, September 12, 2017 at 8:00 a.m. EDT.
Dry eye syndrome is a common inflammatory disease characterized by insufficient moisture and lubrication in the anterior surface of the eye. Symptoms may include ocular irritation, burning or stinging, and severe cases may lead to decreased vision. In patients with dry eye syndrome, aldehydes may contribute to ocular inflammation as well as the impairment of lipids (fats) that lubricate the surface of the eye.
ALDX closed Monday’s trading at $4.20, up 1.20%. In after-hours, the stock was down 5.95% to $3.95.
Fennec Pharmaceuticals Inc.’s (FRX.TO), (FENCF.OB) shares of common stock have been approved for listing on the Nasdaq Capital Market. Trading on the Nasdaq under the symbol “FENC” is expected to commence on September 13, 2017.
Rosty Raykov, CEO of Fennec said, “Our listing on the Nasdaq represents a significant corporate milestone as we continue our commitment towards serving an unmet medical need for pediatric patients with cisplatin chemotherapy pending the SIOPEL 6 results in Q4 2017.”
FENCF.OB closed Monday’s trading at $8.32, up 11.04%.
Shares of Peregrine Pharmaceuticals Inc. (PPHM) rose more than 12% on…